Summary
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar’s developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.
Pharma Mar SA (PHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Pharma Mar SA, Medical Devices Deals, 2011 to YTD 2017 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 12
Merger 12
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 12
Licensing Agreements 13
Eczacibasi Enters into Licensing Agreement with Pharma Mar 13
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 14
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 15
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 16
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 17
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 17
TTY Biopharm Enters into Licensing Agreement with PharmaMar 18
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 19
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 20
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 21
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 22
Pharma Mar SA - Key Competitors 24
Key Employees 25
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 29
Financial Announcements 29
Apr 27, 2017: PharmaMar Group reports €45.5 million in revenues (+8%) 29
Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 30
Oct 27, 2016: PharmaMar Group Reports 9M 2016 Financial Results 32
Jul 26, 2016: Pharma Mar Group Reports 1H 2016 Financial Results 33
Apr 28, 2016: PharmaMar Group Reports Q1 2016 Financial Results 34
Government and Public Interest 35
Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 35
Product News 37
Dec 01, 2016: PharmaMar presents positive results with its conjugated antibody MI130110 in CD13-experssing tumor-cells 37
Jun 16, 2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 38
May 18, 2016: Janssen to Present Data on Trabectedin at the 2016 American Society of Clinical Oncology Annual Meeting 39
May 06, 2016: Early diagnosis, a multidisciplinary approach and access to new therapies, key in the treatment of ovarian cancer 40
Apr 27, 2017: PharmaMar demonstrates its progress in R&D in New York 42
Apr 14, 2016: PharmaMar Announces Presentation on Plitidepsin at American Association for Cancer Research (AACR) Annual Meeting 2016 43
Apr 14, 2016: PharmaMar Announces Presentation on PM1183 at American Association for Cancer Research (AACR) Annual Meeting 2016 44
Apr 14, 2016: PharmaMar Announces Presentation on PM184 at American Association for Cancer Research (AACR) Annual Meeting 2016 45
Apr 04, 2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 46
Mar 03, 2016: Yondelis Approved for Sale in 6 Additional Countries 47
Product Approvals 48
Oct 28, 2016: The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin 48
Sep 22, 2016: PharmaMar submits MAA to EMA for Aplidin for the treatment of multiple myeloma 49
Clinical Trials 50
Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 50
May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 51
Nov 28, 2016: PharmaMar Begins a Phase I studyof PM1183 in Japan for the Treatment of Solid Tumors 52
Nov 10, 2016: PharmaMar shows new clinical data on PM1183 (lurbinectedin) at CTOS 2016 53
Nov 10, 2016: PharmaMar shows new clinical data on Yondelis (trabectedin) at CTOS 2016 54
Oct 31, 2016: PharmaMar is present at the 16th International Gynecologic Cancer Society Meeting with new evidence on Yondelis 56
Oct 18, 2016: PharmaMar completes the patient recruitment for the “CORAIL” Phase III pivotal study with PM1183 57
Oct 10, 2016: PharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 - Associated Metastatic Breast Cancer at the ESMO 2016 Congress 58
Oct 05, 2016: PharmaMar announces new clinical data on lurbinectedin (PM1183) to be presented at ESMO 2016 59
Oct 05, 2016: PharmaMar announces new clinical data on Yondelis to be presented at ESMO 2016 61
Aug 11, 2016: PharmaMar Announces the IDMCs Response on the CORAIL Trial Using PM1183 62
Aug 02, 2016: PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin in patients with small cell lung cancer 63
Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma 64
May 20, 2016: PharmaMar begins a Phase I study of lurbinectedin in combination with irinotecan for the treatment of solid tumors 65
May 19, 2016: PharmaMar Announces New Data on PM1183 to be Presented at 2016 ASCO Annual Meeting 66
May 19, 2016: PharmaMar Announces New Data on Yondelis at 2016 ASCO Annual Meeting 67
May 19, 2016: PharmaMar reports positive results from the Phase I study of Aplidin (plitidepsin) in combination with bortezomib and dexamethasone in patients with multiple myeloma at the 2016 ASCO Annual Meeting 68
Mar 31, 2016: Aplidin shows positive results in pivotal Phase III clinical trial for multiple myeloma 69
Feb 26, 2016: PharmaMar initiates a Phase II trial with antitumour drug PM184 in advanced breast cancer 70
Feb 08, 2016: The Phase III Clinical Trial Using PM1183 in Treating Ovarian Cancer Continues Following the IDMC's Positive Recommendation 71
Other Significant Developments 72
Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73
List of Tables
Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pharma Mar SA, Deals By Therapy Area, 2011 to YTD 2017 9
Pharma Mar SA, Medical Devices Deals, 2011 to YTD 2017 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 12
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 12
Eczacibasi Enters into Licensing Agreement with Pharma Mar 13
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 14
Chugai Pharma Enters into Licensing Agreement with Pharma Mar 15
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 16
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 17
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 17
TTY Biopharm Enters into Licensing Agreement with PharmaMar 18
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 19
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 20
PharmaMar Enters Into Licensing Agreement With Janssen Products For Yondelis 21
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 22
Pharma Mar SA, Key Competitors 24
Pharma Mar SA, Key Employees 25
Pharma Mar SA, Subsidiaries 27List of Figures
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Pharma Mar SA, Medical Devices Deals, 2011 to YTD 2017 10
